title: Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study).
authors.affiliation: Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA.
authors.forename: Wu
authors.initials: W
authors.lastname: Zhang
authors.forename: Mizutomo
authors.initials: M
authors.lastname: Azuma
authors.forename: Georg
authors.initials: G
authors.lastname: Lurje
authors.forename: Michael A
authors.initials: MA
authors.lastname: Gordon
authors.forename: Dongyun
authors.initials: D
authors.lastname: Yang
authors.forename: Alexandra
authors.initials: A
authors.lastname: Pohl
authors.forename: Yan
authors.initials: Y
authors.lastname: Ning
authors.forename: Pierre
authors.initials: P
authors.lastname: Bohanes
authors.forename: Armin
authors.initials: A
authors.lastname: Gerger
authors.forename: Thomas
authors.initials: T
authors.lastname: Winder
authors.forename: Ellen
authors.initials: E
authors.lastname: Hollywood
authors.forename: Kathleen D
authors.initials: KD
authors.lastname: Danenberg
authors.forename: Leonard
authors.initials: L
authors.lastname: Saltz
authors.forename: Heinz-Josef
authors.initials: HJ
authors.lastname: Lenz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000235:genetics*; D019008:Drug Resistance, Neoplasm; D005260:Female; D015870:Gene Expression; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011237:Predictive Value of Tests; D015996:Survival Rate; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000077146:Irinotecan; D000068818:Cetuximab; D002166:Camptothecin